Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters

Immunobiology

Volumn 220, Issue 4, 2015, Pages 476-482

  Reis, Edimara S ^a   DeAngelis, Robert A ^a   Chen, Hui ^a   Resuello, Ranillo R G ^b   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Simian Conservation Breeding and Research Center   (Philippines)

Author keywords

C3; Complement; Compstatin; Cp40; Hemodialysis

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; CP40 PEPTIDE; INTERLEUKIN 10; POLYMER; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG POTENCY; FILTER; HEMODIALYSIS; HEMODIALYSIS MACHINE; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; IMMUNOLOGY; MICROPORE FILTER; RENAL REPLACEMENT THERAPY; SYNTHESIS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; INTERLEUKIN-10; MACACA FASCICULARIS; MICROPORE FILTERS; MODELS, ANIMAL; PEPTIDES; RENAL DIALYSIS;

EID: 84925129848     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.10.026     Document Type: Article

References (34)

1. Bologa R.M., Levine D.M., Parker T.S., Cheigh J.S., Serur D., Stenzel K.H., Rubin A.L. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998, 32:107-114.
2. Cavalli A., Del Vecchio L., Manzoni C., Locatelli F. Hemodialysis: yesterday, today and tomorrow. Minerva Urol. Nefrol. 2010, 62:1-12.
3. Chi Z.L., Yoshida T., Lambris J.D., Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 2010, 703:127-135.
4. DeAngelis R.A., Reis E.S., Ricklin D., Lambris J.D. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 2012, 217:1097-1105.
5. Ekdahl K.N., Lambris J.D., Elwing H., Ricklin D., Nilsson P.H., Teramura Y., Nicholls I.A., Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 2011, 63:1042-1050.
6. Fiane A.E., Mollnes T.E., Videm V., Hovig T., Hogasen K., Mellbye O.J., Spruce L., Moore W.T., Sahu A., Lambris J.D. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 1999, 6:52-65.
7. Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol. Dial. Transplant. 2007, 22(Suppl. 5):v20-v36.
8. Huang Y., Reis E.S., Knerr P.J., van der Donk W.A., Ricklin D., Lambris J.D. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. Chem. Med. Chem. 2014, 9:2223-2226.
9. Jain U., Woodruff T.M., Stadnyk A.W. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br. J. Pharmacol. 2013, 168:488-501.
10. Jofre R., Rodriguez-Benitez P., Lopez-Gomez J.M., Perez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J. Am. Soc. Nephrol. 2006, 17:S274-S280.
11. Kimmel P.L., Phillips T.M., Simmens S.J., Peterson R.A., Weihs K.L., Alleyne S., Cruz I., Yanovski J.A., Veis J.H. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998, 54:236-244.
12. Kourtzelis I., Markiewski M.M., Doumas M., Rafail S., Kambas K., Mitroulis I., Panagoutsos S., Passadakis P., Vargemezis V., Magotti P., Qu H., Mollnes T.E., Ritis K., Lambris J.D. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010, 116:631-639.
13. Kourtzelis I., Rafail S., DeAngelis R.A., Foukas P.G., Ricklin D., Lambris J.D. Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. FASEB J. 2013, 27:2768-2776.
14. Macdougall I.C., Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 2002, 17(Suppl. 11):39-43.
15. Maekawa T., Abe T., Hajishengallis E., Hosur K.B., DeAngelis R.A., Ricklin D., Lambris J.D., Hajishengallis G. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J. Immunol. 2014, 192:6020-6027.
16. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 2007, 44:82-94.
17. NKUDIC Kidney and urologic diseases statistics for the United States. National Kidney & Urologic Diseases Information Clearinghouse (NKUDIC) - A Service of the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) 2012, National Institutes of Health (NIH), (2-15-2012. 5-30-2012).
18. Oppermann M., Haubitz M., Quentin E., Gotze O. Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B. Klin. Wochenschr. 1988, 66:857-864.
19. Qu H., Magotti P., Ricklin D., Wu E.L., Kourtzelis I., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol. Immunol. 2011, 48:481-489.
20. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013, 218:496-505.
21. Rao M., Guo D., Perianayagam M.C., Tighiouart H., Jaber B.L., Pereira B.J., Balakrishnan V.S. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2005, 45:324-333.
22. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
23. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273-292.
24. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831-3838.
25. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 2013, 190:3839-3847.
26. Risitano A.M., Ricklin D., Huang Y., Reis E.S., Chen H., Ricci P., Lin Z., Pascariello C., Raia M., Sica M., Del V.L., Pane F., Lupu F., Notaro R., Resuello R.R., DeAngelis R.A., Lambris J.D. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123:2094-2101.
27. Roux S., Zekri E., Rousseau B., Paternostre M., Cintrat J.C., Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J. Pept. Sci. 2008, 14:354-359.
28. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
29. Soulika A.M., Khan M.M., Hattori T., Bowen F.W., Richardson B.A., Hack C.E., Sahu A., Edmunds L.H., Lambris J.D. Inhibition of heparin/protamine complex-induced complement activation by compstatin in baboons. Clin. Immunol. 2000, 96:212-221.
30. Stenvinkel P., Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 2002, 15:329-337.
31. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., Heimburger O., Cederholm T., Girndt M. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005, 67:1216-1233.
32. Wu Y.Q., Qu H., Sfyroera G., Tzekou A., Kay B.K., Nilsson B., Nilsson Ekdahl K., Ricklin D., Lambris J.D. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 2011, 186:4269-4277.
33. Yeun J.Y., Levine R.A., Mantadilok V., Kaysen G.A. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000, 35:469-476.
34. Zaritsky J.J., Kalantar-Zadeh K. The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?. J. Am. Soc. Nephrol. 2012, 23:189-191.